# Let non-profits and academics add a cancer indication to an off-patent drug's label

Source: https://onco.cc/ideas/idea-reg-third-party-label-update/  
OnCo record `idea-reg-third-party-label-update` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Only the manufacturer can ask regulators to add a new use to a drug's label, and generic makers have no reason to. Universities and charities should be allowed to apply.

## Summary

When a publicly funded trial proves an old drug works in cancer, the result rarely reaches the label because no marketing authorisation holder will file, leaving the indication off-label with weak reimbursement and guideline status. The EU's 2023 pharmaceutical reform proposal includes a mechanism for non-commercial entities to submit evidence for a new indication, which the regulator can then require all holders to include; the FDA has no equivalent. The proposal is a formal third-party supplement pathway in FDA, EMA and other regulators, with fee waivers, allowing academic sponsors to file, and a label change binding on all generic versions.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Within five years of the pathway opening, at least five off-patent drugs gain oncology indications through third-party filings, and reimbursement and guideline adoption of those indications follow within a year of labelling.
- Rationale: The label is the hinge on which reimbursement, guidelines and prescribing turn; a pathway that decouples label updates from the commercial interest of the holder removes the last barrier for proven repurposed drugs.
- Proposed test: Pass the EU provision and pilot an FDA equivalent; file the first two academic supplements (for example a positive repurposing trial result) and measure time to label change and downstream reimbursement.
- Maturity: early-clinical
- Actor: regulator

## Sources

- EU pharmaceutical legislation reform: https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_en

## Connected records

- bottlenecks: [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-third-party-label-update.json